AWS launched Amazon Bio Discovery, an agentic AI platform intended to speed antibody drug discovery by connecting model selection, candidate evaluation, and lab-in-the-loop synthesis and testing. The system uses a benchmarked library of biological foundation models and an AI agent that routes outputs to laboratory partners once in silico work identifies candidates. AWS described a workflow using Twist Bioscience and Ginkgo Bioworks wet-lab capabilities, reporting that researchers designed nearly 300,000 antibodies and quickly produced and tested the most promising subset in weeks rather than traditional timelines. Early adopters cited by AWS include major research and pharma organizations. Analysts signaled optimism for expanded AI use in discovery, while also noting competitive dynamics around CRO protein characterization and the challenge of translating AI efforts into near-term revenue.